Skip to main content
Erschienen in: International Cancer Conference Journal 4/2017

10.07.2017 | Case report

Case of painless thyroiditis that developed during adjuvant chemotherapy for breast cancer

verfasst von: Asumi Iesato, Takaaki Oba, Koichi Ono, Takayuki Watanabe, Tokiko Ito, Toshiharu Kanai, Kazuma Maeno, Ken-ichi Ito

Erschienen in: International Cancer Conference Journal | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

We report a case of painless thyroiditis that occurred during adjuvant chemotherapy for breast cancer. A 41-year-old woman was diagnosed with right breast cancer and underwent surgery followed by adjuvant chemotherapy, given the tumor size and relatively high ratio of Ki-67-positive cells. Three weeks after the first intravenous administration of fluorouracil (500 mg/m2), epirubicin (100 mg/m2), cyclophosphamide (500 mg/m2), and dexamethasone (6.6 mg/body), followed by 3 days of oral dexamethasone (8 mg/day), she complained of continued palpitations. Although Graves’ disease was initially suspected, she was diagnosed with painless thyroiditis because of a low free T3:free T4 ratio and low thyroid uptake of iodine. The mechanism of painless thyroiditis, in this case, remains unclear, although supposed etiologic event was the use of cytotoxic drugs (including fluorouracil) or the withdrawal of short-term steroid administration. Painless thyroiditis very rarely occurs during chemotherapy. However, we should consider painless thyroiditis when a patient undergoing cytotoxic chemotherapy for breast cancer experiences continued palpitations. The appropriate diagnosis and treatment of symptoms might avoid an unnecessary dose reduction or discontinuation of chemotherapy and, moreover, may prevent adverse effects associated with the metabolism of anticancer agents.
Literatur
1.
2.
Zurück zum Zitat Bindra A, Braunstein GD (2006) Thyroiditis. Am Fam Physician 73:1769–1776PubMed Bindra A, Braunstein GD (2006) Thyroiditis. Am Fam Physician 73:1769–1776PubMed
5.
Zurück zum Zitat Torino F, Barnabei A, Paragliola RM et al (2013) Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid 23:1345–1366CrossRefPubMed Torino F, Barnabei A, Paragliola RM et al (2013) Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid 23:1345–1366CrossRefPubMed
6.
Zurück zum Zitat Fauci AS, Braunwald E, Kasper DL et al (2008) Disorders of the thyroid gland. Harrison’s principles of internal medicine, 17th edn. McGraw-Hill Professional, New York, pp 2224–2247 Fauci AS, Braunwald E, Kasper DL et al (2008) Disorders of the thyroid gland. Harrison’s principles of internal medicine, 17th edn. McGraw-Hill Professional, New York, pp 2224–2247
7.
Zurück zum Zitat Beex L, Ross A, Smals A et al (1977) 5-Fluorouracil-induced increase of total serum thyroxine and triiodothyronine. Cancer Treat Rep 61:1291–1295PubMed Beex L, Ross A, Smals A et al (1977) 5-Fluorouracil-induced increase of total serum thyroxine and triiodothyronine. Cancer Treat Rep 61:1291–1295PubMed
8.
Zurück zum Zitat Morita S, Ueda Y, Yokoyama N (2001) Painless thyroiditis induced by the cessation of betamethasone. Intern Med 40:744–746CrossRefPubMed Morita S, Ueda Y, Yokoyama N (2001) Painless thyroiditis induced by the cessation of betamethasone. Intern Med 40:744–746CrossRefPubMed
9.
Zurück zum Zitat Maruyama H, Kato M, Mizuno O et al (1982) Transient thyrotoxicosis occurred after cessation of steroid therapy in a patient with autoimmune thyroiditis and rheumatoid arthritis. Endocrinol Jpn 29:583–588CrossRefPubMed Maruyama H, Kato M, Mizuno O et al (1982) Transient thyrotoxicosis occurred after cessation of steroid therapy in a patient with autoimmune thyroiditis and rheumatoid arthritis. Endocrinol Jpn 29:583–588CrossRefPubMed
10.
Zurück zum Zitat Haraguchi K, Hiramatsu K, Onaya T (1984) Transient thyrotoxicosis after unilateral adrenalectomy in two patients with Cushing’s syndrome. Endocrinol Jpn 31:577–582CrossRefPubMed Haraguchi K, Hiramatsu K, Onaya T (1984) Transient thyrotoxicosis after unilateral adrenalectomy in two patients with Cushing’s syndrome. Endocrinol Jpn 31:577–582CrossRefPubMed
11.
Zurück zum Zitat Morita T, Tamai H, Oshima A et al (1990) The occurrence of thyrotropin binding-inhibiting immunoglobulins and thyroid-stimulating antibodies in patients with silent thyroiditis. J Clin Endocrinol Metab 71:1051–1055CrossRefPubMed Morita T, Tamai H, Oshima A et al (1990) The occurrence of thyrotropin binding-inhibiting immunoglobulins and thyroid-stimulating antibodies in patients with silent thyroiditis. J Clin Endocrinol Metab 71:1051–1055CrossRefPubMed
Metadaten
Titel
Case of painless thyroiditis that developed during adjuvant chemotherapy for breast cancer
verfasst von
Asumi Iesato
Takaaki Oba
Koichi Ono
Takayuki Watanabe
Tokiko Ito
Toshiharu Kanai
Kazuma Maeno
Ken-ichi Ito
Publikationsdatum
10.07.2017
Verlag
Springer Japan
Erschienen in
International Cancer Conference Journal / Ausgabe 4/2017
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-017-0303-0

Weitere Artikel der Ausgabe 4/2017

International Cancer Conference Journal 4/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.